



0364

Attorney Docket No.: 10017.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al. Confirmation No: 5362  
Serial No.: 09/784,554 Group Art Unit: 1651  
Filed: February 16, 2001 Examiner: To be assigned  
For: Family 44 Xyloglucanases

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box Sequence  
Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to Comply with Sequence Rules
2. Copy of Notice to Comply with Sequence Rules
3. Disk Containing Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence  
Commissioner for Patents  
Washington, DC 20231

on October 24, 2001.

Julie Tabarovsky  
(name of person mailing paper)

*J. Tabarovsky*  
(signature of person mailing paper)



Attorney Docket No.: 10017.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schnorr et al.                      Confirmation No: 5362  
Serial No.: 09/784,554                                      Group Art Unit: 1651  
Filed: February 16, 2001                                      Examiner: To be assigned  
For: Family 44 Xyloglucanases

**AMENDMENT AND RESPONSE TO NOTICE TO FILE MISSING PARTS  
AND TO NOTICE TO COMPLY WITH SEQUENCE RULES**

Box Sequence  
Commissioner for Patents  
Washington, DC 20231


Sir:


In response to the Notice to Comply with Sequence Rules dated October 22, 2001, Applicants enclose a computer readable form of the Sequence Listing mailed on July 2, 2001. The content of the paper copy and of the computer readable form is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: October 24, 2001

  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/784,554	02/16/2001	Kirk Schnorr	10017.200-US

CONFIRMATION NO. 5362

## FORMALITIES LETTER



\*OC000000006946836\*

25908  
NOVOZYMES NORTH AMERICA, INC.  
C/O NOVO NORDISK OF NORTH AMERICA, INC.  
405 LEXINGTON AVENUE, SUITE 6400  
NEW YORK, NY 10174

Date Mailed: 10/22/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE